Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of the potential for the drug Daraxonrasib to treat advanced pancreatic cancer; and when they expect the National Institute for Health and Care to complete their technology appraisal of the drug.

Daraxonrasib is not currently licensed in the United Kingdom. Should the manufacturer submit an application to the Medicines and Healthcare products Regulatory Agency (MHRA) for a product licence, the MHRA has processes in place to review and assess its benefit-risk in relation to quality, safety, and efficacy.

The National Institute for Health and Care Excellence (NICE) is responsible for providing evidence‑based recommendations on whether new, licensed medicines represent a clinically and cost‑effective use of National Health Service resources. Daraxonrasib is not currently included in NICE’s work programme. If the manufacturer submits a licensing application to the MHRA for daraxonrasib it will be considered by NICE for evaluation.